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The addition of sildenafil to nintedanib treatment does not improve outcomes to a greater 
extent than monotherapy with nintedanib, and it is not recommended for IPF subjects  
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Context
Idiopathic pulmonary fibrosis (IPF) is a chronic 
disease characterised by progressive lung interstitial 
fibrosis of unknown cause [1]. IPF incidence 
increases with older age and clinical manifestations 
include dry cough, exertional dyspnoea and overall 
progressive deterioration of patient quality of life 
(QOL) [1]. In the past decade, new treatment 
options have become available to treat IPF, such 
as nintedanib, an intracellular tyrosine kinase 
inhibitor. The INPULSIS trials evaluated the efficacy 
and safety of nintedanib versus placebo in 1066 IPF 
patients with a diffusing capacity of the lung for 
carbon monoxide (DLCO) of 30–79% of the predicted 
value [2]. These trials showed that treatment 
with nintedanib slowed the rate of forced vital 
capacity (FVC) decline but no significant difference 
was observed in the St George’s Respiratory 
Questionnaire (SGRQ) score [2].
Sildenafil is a phosphodiesterase-5 inhibitor 
used frequently to treat pulmonary hypertension. 
The sildenafil trial of exercise performance in IPF 
(STEP-IPF) included 180 patients with a DLCO 
<35% predicted, randomised to sildenafil or 
placebo [3]. There was no significant difference in 
6-min walk distance between groups, but stability 
of QOL questionnaire scores was observed in the 
sildenafil group while scores of the placebo group 
worsened [3].
Current IPF treatment guidelines do not 
recommend the routine use of sildenafil. 
Furthermore, previous clinical trials with antifibrotic 
medication in IPF excluded patients with severe 
functional impairment [4]. Therefore, investigators 
for the INSTAGE trial aimed to assess the potential 
benefits of the combined nintedanib plus sildenafil 
therapy for IPF patients with severe disease [5].
Methods
This was a randomised, double-blind, multicentre 
and parallel-group study including 13 countries. 
Study participants were ≥40 years old, diagnosed 
with IPF in the previous 6 years and with a DLCO 
≤35% of predicted value. Participants were 
randomly assigned in a 1:1 ratio to a treatment 
group of nintedanib (150 mg twice daily) plus 
sildenafil (20 mg three times daily) or to the 
nintedanib (150 mg twice daily) plus placebo (three 
times daily) group for 24 weeks. Echocardiographic 
signs suggestive of right heart dysfunction were 
used for stratification of randomised patients. 
The primary end-point was change in the SGRQ 
score at week 12, which was analysed according to 
demographic data, presence of echocardiographic 
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signs indicative of right heart dysfunction, 
FVC and DLCO percentage of predicted values, 
presence of emphysema, and history of previous 
treatment with nintedanib. Secondary end-points 
were: 1) change in the SGRQ score at week 24; 2) 
change in the University of California, San Diego, 
Shortness of Breath Questionnaire (UCSD-SOBQ) 
and the EuroQol Group 5-Dimension Self-Report 
Questionnaire (EQ-5D) visual-analogue scale scores 
at weeks 12 and 24; 3) percentage of patients with 
serious adverse events; 4) FVC, oxygen saturation 
and DLCO at weeks 12 and 24; 5) change in brain 
natriuretic peptide (BNP) levels at week 24; 6) 
proportion of patients with an absolute decline of 
≥5 percentage points of predicted value or death; 
7) proportion of patients with a relative decline of 
≥10% decline of the predicted FVC value or death; 
8) proportion of patients with ≥15% decline in DLCO; 
9) acute exacerbations; and 10) death from any 
cause, among others.
Main results
A total of 274 patients were randomised over a 
14-month period, 138 of whom were assigned to 
the nintedanib-plus-sildenafil group and 136 to the 
nintedanib-plus-placebo group. Baseline patient 
characteristics did not differ amongst groups. 
Mean change from baseline SGRQ total score at 
week 12 was −1.28 points for the nintedanib-
plus-sildenafil group and −0.77 for the nintedanib-
plus-placebo group (p=0.72), and 0.23 points and 
2.42 points, respectively, at week 24 (95% CI 
−5.40–1.03). Therefore, the primary end-point was 
not significant. The p-values for all other analyses 
were not reported, as they were considered to be 
exploratory. No significant changes in the UCSD-
SOBQ scores were identified at week 12 (between-
group difference −2.94 points, 95% CI −7.27–1.39) 
or at week 24 (between-group difference −2.41 
points, 95% CI −7.39–2.58). Also, there were no 
meaningful changes in the EQ-5D visual-analogue 
scale scores at weeks 12 or 24 (between-group 
difference 3.54 points (95% CI −0.02–7.09) and 
1.50 points (95% CI −2.86–5.86), respectively).
The nintedanib-plus-sildenafil group had a lower 
risk of FVC decline of ≥5 percentage points or death 
(31.4% versus 50.7% of patients; hazard ratio (HR) 
0.56, 95% CI 0.38–0.82) compared to the placebo 
group. Moreover, the sildenafil group had a lower 
percentage of patients with an FVC decline of ≥10% 
or death (25.5% versus 36.8%; HR 0.68, 95% CI 
0.44–1.05).
No relevant differences were found among 
groups for oxygen saturation, DLCO, acute 
exacerbations or death from any cause. BNP levels 
at week 24, however, showed a mean change 
from baseline of −11.6 ng·L−1 and 39.7 ng·L−1 in 
the nintedanib-plus-sildenafil and the nintedanib-
plus-placebo groups, respectively (difference 
−51.3 ng·L−1, 95% CI −85.1– −17.6).
Finally, no important differences regarding the 
occurrence of adverse events and severe adverse 
events were detected between treatment groups.
Commentary
Choosing a primary end-point in clinical trials for 
IPF treatment is a difficult and complex decision. 
So far, FVC is the measurement used in most phase 
III clinical trials for IPF as a surrogate primary end-
point, but its significance is still controversial [6, 7]. 
Nevertheless, both nintedanib and pirfenidone 
treatments were approved by the US Food and 
Drug Administration for IPF, as they showed a 
significant effect on FVC decline when compared 
to placebo [2, 8, 9]. IPF is a chronic and progressive 
disease that affects patients in almost every aspect 
of their lives, so prolonging life and slowing down 
FVC decline alone may not be enough to measure 
the impact of pharmacological treatment. The use 
of patient-reported outcome measures, such as 
disease-specific questionnaires, allows physicians 
to assess nonphysiological aspects of the patient 
and the disease [10]. In this regard, several tools 
have been validated for IPF and are of great use not 
only for clinical trials but also for routine clinical 
practice [10, 11]. INSTAGE is the first treatment trial 
whose primary end-point was to improve QOL in IPF 
patients. This study used patient-related outcome 
measures to assess the impact of adding sildenafil 
to treatment with nintedanib, but it failed to show 
significant benefits regarding QOL measured by the 
SGRQ, UCSD-SOBQ or EQ-5D visual-analogue scale 
scores in this cohort of IPF patients with severe 
pulmonary gas exchange impairment. As stated 
by the investigators, it is possible that the study 
was underpowered, which could have affected the 
outcome, but other aspects may also contribute to 
obtaining these negative results. Both nintedanib 
and sildenafil treatments are frequently associated 
with side-effects that worsen patient QOL. Although 
no statistical differences were detected regarding 
occurrence of serious or severe adverse events 
between treatment groups, a higher occurrence 
of diarrhoea, nausea, vomiting, headaches, cough 
and dyspnoea was reported in the nintedanib-
plus-sildenafil group. Moreover, QOL is influenced 
by the presence of symptoms, exercise capacity, 
nutrition status or psychological burden, among 
others, but nintedanib and sildenafil have little 
effect in improving these aspects. Therefore, since 
no specific approach was used to address such 
issues, INSTAGE was less likely to find a significant 
QOL improvement.
This is one of the few clinical trials that includes 
IPF subjects with a DLCO <35% of predicted, a 
subgroup of patients that has been poorly studied. 
A lower risk of FVC decline of ≥5 percentage points 
of predicted value or death was observed in subjects 
treated with nintedanib plus sildenafil, although 
these results should be interpreted carefully as they 
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differ with previous trials of endothelin receptor 
antagonist therapy in IPF [12, 13]. Nevertheless, 
changes in FVC and safety and side-effect profile in 
the nintedanib-plus-placebo group were similar to 
those observed in previous trials including patients 
with mild to moderate disease [2].
Finally, an absence of BNP level increase was 
observed in the nintedanib-plus-sildenafil group. 
This result, possibly related to the effect of sildenafil 
on vascular remodelling and right ventricular stress 
reduction [14, 15], may imply that the addition of 
sildenafil to antifibrotic therapy could have a larger 
impact in IPF patients with pulmonary hypertension 
and right ventricular dysfunction. Further trials are 
required and could be of great interest to assess 
this effect.
Implications for practice
Nintedanib is a safe and effective treatment for IPF 
patients. It can be considered for individuals with 
severe disease, as the safety profile and changes in 
FVC observed in the nintedanib-plus-placebo group 
were similar to those found in previous studies with 
mild–moderate IPF. The addition of sildenafil to 
nintedanib therapy does not improve QOL compared 
to nintedanib alone and is not recommended for IPF 
patients. However, it may have a beneficial effect in 
a specific subgroup of individuals with pulmonary 
hypertension and right ventricular dysfunction, but 
more studies are needed to confirm and quantify 
this potential effect.
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